Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Phendimetrazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 5/20 | 0.50 |
| ▸ | SLC6A3 known ✓ | Q01959 | 5/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.96 |
| ▸ | HTR2B | P41595 | 2/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phendimetrazine SCHEMBL598950 | 0.98 | HTR1A (1.00) | HTR1ASLC6A2SLC6A3HTR2BADRA1A | |
| Phendimetrazine SCHEMBL49481 | 0.98 | HTR1A (1.00) | HTR1ASLC6A2SLC6A3HTR2BADRA1A | |
| Phendimetrazine SCHEMBL344020 | 0.98 | HTR1A (1.00) | HTR1ASLC6A2SLC6A3HTR2BADRA1A | |
| Phendimetrazine SCHEMBL15064942 | 0.98 | HTR1A (1.00) | HTR1ASLC6A2SLC6A3HTR2BADRA1A | |
| Phendimetrazine SCHEMBL678073 | 0.95 | HTR1A (0.93) | HTR1ASLC6A2SLC6A3HTR2BADRA1A | |
| Phendimetrazine SCHEMBL160376 | 0.85 | HTR1A (0.75) | HTR1ASLC6A2SLC6A3HTR2BADRA1A | |
| Phendimetrazine SCHEMBL29353044 | 0.85 | HTR1A (0.75) | HTR1ASLC6A2SLC6A3HTR2BADRA1A | |
| Phendimetrazine SCHEMBL160375 | 0.85 | HTR1A (0.75) | HTR1ASLC6A2SLC6A3HTR2BADRA1A | |
| Phendimetrazine SCHEMBL29554688 | 0.85 | HTR1A (0.75) | HTR1ASLC6A2SLC6A3HTR2BADRA1A | |
| Phendimetrazine SCHEMBL4381184 | 0.85 | HTR1A (0.75) | HTR1ASLC6A2SLC6A3HTR2BADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000653-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250326761-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12435080-B2 | sGC stimulators | TISENTO THERAPEUTICS INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250243205-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2025-07-31 | — | — | US | disclosed |
| US-20250115611-A1 | CRYSTALLINE FORMS OF 8-(2-FLUOROBENZYL)-6-(3-(TRIFLUOROMETHYL)-1H-1,2,4-TRIAZOL-5-YL)IMIDAZO[1,2-a]PYRAZINE AS sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2025-04-10 | — | — | US | disclosed |
| US-20250108040-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2025-04-03 | — | — | US | disclosed |
| US-20250059197-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2025-02-20 | — | — | US | disclosed |
| US-12220414-B2 | Use of sGC stimulators for the treatment of mitochondrial disorders | TISENTO THERAPEUTICS INC. (US) | 2025-02-11 | — | — | US | disclosed |
| US-12122782-B2 | Crystalline forms of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine as sGC stimulators | TISENTO THERAPEUTICS INC. (US) | 2024-10-22 | — | — | US | disclosed |
| US-20240342188-A1 | Use of NEP Inhibitors for the Treatment of Laminitis | CURTAILS LLC (US) | 2024-10-17 | — | — | US | disclosed |
| US-20070244143-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC (US) | 2007-10-18 | — | — | US | disclosed |
| WO-2007104035-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20070208029-A1 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| WO-2007053596-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007047978-A2 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | BRAINCELLS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2007030697-A2 | MODULATION OF NEUROGENESIS BY HDAC INHIBITION | BRAINCELLS, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007025177-A2 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | GABRB2, GAP43, GABRB1 | SLC6A2 330/4885SLC6A3 266/4885HTR1A 777/4885 |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | DCX, BDNF, NTRK2 | SLC6A2 2832/4885SLC6A3 2839/4885HTR1A 3606/4885 |
| US-12220414-B2 | Use of sGC stimulators for the treatment of mitochondrial disorders | CS, COQ8A, GLS | SLC6A2 2145/4885SLC6A3 2569/4885HTR1A 3404/4885 |
| US-20250059197-A1 | sGC STIMULATORS | GMPS, GUCY1A2, PDE2A | SLC6A2 1983/4885SLC6A3 2536/4885HTR1A 1929/4885 |
| US-20250326761-A1 | sGC STIMULATORS | GUCY1A2, PRKG1, GMPS | SLC6A2 2812/4885SLC6A3 3555/4885HTR1A 1614/4885 |
| US-12435080-B2 | sGC stimulators | GUCY1A2, PRKG1, PDE2A | SLC6A2 3025/4885SLC6A3 3515/4885HTR1A 1751/4885 |
| US-20070208029-A1 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | PDE2A, PDE4A, DCX | SLC6A2 1018/4885SLC6A3 777/4885HTR1A 1691/4885 |
| US-20070244143-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | GAP43, BDNF, DCX | SLC6A2 295/4885SLC6A3 333/4885HTR1A 385/4885 |
| US-12122782-B2 | Crystalline forms of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine as sGC stimulators | GUCY1A2, GUCY1B2, GUCY1A1 | SLC6A2 3694/4885SLC6A3 4068/4885HTR1A 756/4885 |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | SLC6A2 1348/4885SLC6A3 1109/4885HTR1A 486/4885 |
| US-20260000653-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | PDE9A, PDE2A, GUCY1A2 | SLC6A2 99/4885SLC6A3 140/4885HTR1A 1249/4885 |
| US-20250115611-A1 | CRYSTALLINE FORMS OF 8-(2-FLUOROBENZYL)-6-(3-(TRIFLUOROMETHYL)-1H-1,2,4-TRIAZOL-5-YL)IMIDAZO[1,2-a]PYRAZINE AS sGC STIMULATORS | GUCY1A2, GUCY1B2, GUCY1A1 | SLC6A2 3694/4885SLC6A3 4068/4885HTR1A 756/4885 |
| US-20240342188-A1 | Use of NEP Inhibitors for the Treatment of Laminitis | MME, REN, ACE | SLC6A2 79/4885SLC6A3 824/4885HTR1A 1475/4885 |
| US-20250243205-A1 | sGC STIMULATORS | GMPS, GUCY1A2, PDE2A | SLC6A2 1983/4885SLC6A3 2536/4885HTR1A 1929/4885 |
| US-20250108040-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | GUCY1A2, GUCY1B2, PDE2A | SLC6A2 710/4885SLC6A3 668/4885HTR1A 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.